Excited to share our lab's latest discovery today in @Nature: "orthosteric molecular glue” (OMG) inhibitors - a new drug design strategy that achieves substrate-dependent potency, i.e., substrate selectivity, with conventional orthosteric inhibitors. https://t.co/U5Y6JBoJql
By selectively inhibiting an enzyme’s activity toward a specific disease-relevant substrate while sparing others, OMG inhibitors could provide a more refined alternative in drug design - enabling the development of treatments that are more effective & better tolerated by patients
Together with Michele Pagano's lab at NYU, we are excited to share a new story on two F-box protein E3 ligases recognizing two distinct & mutually exclusive degrons encrypted in the quaternary structure of the substrate protein https://t.co/UbVCBnJK8g
Story 1: UM171 asymmetrically reprograms dimeric CRL3-KBTBD4 to degrade CoREST via HDAC1/2 with InsP6 as a second glue. Story (2): Cancer mutations of KBTBD4 found in medulloblastoma structurally, functionally, and mechanistically mimic UM171. https://t.co/yjUQoEkmN3
Together with labs of @brian_b_liau and Philip Cole and many other collaborators, we are excited to share a new molecular glue story with many surprises. https://t.co/zyoYf2pMNM
Finally! Many thanks to my Ph.D. supervisor Dr. Xinzheng Zhang and my labmate Ph.D. candidate Chunling Wu. Low-cooling-rate freezing in biomolecular cryo-electron microscopy for recovery of initial frames https://t.co/JkN0ThLJ76